[{"id":"8abb3331-04ba-4bfa-a734-5fadb9a6b09e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04458259","created_at":"2021-08-31T17:53:09.115Z","updated_at":"2024-07-02T16:35:11.509Z","phase":"Phase 1","brief_title":"Study of PF-07265807 in Participants With Metastatic Solid Tumors.","source_id_and_acronym":"NCT04458259","lead_sponsor":"Pfizer","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib • Zumrad (sasanlimab) • PF-07265807"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 09/24/2020","start_date":" 09/24/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-03"}]